NCT02447315 is a Phase 1 clinical trial of Pilocarpine in Healthy Subjects, sponsored by Astellas Pharma Europe B.V..

Who is sponsoring NCT02447315?

NCT02447315 is sponsored by Astellas Pharma Europe B.V..

What drugs are being tested in NCT02447315?

Interventions in NCT02447315: Pilocarpine, Placebo.

What condition does NCT02447315 study?

NCT02447315 studies Healthy Subjects.

Is NCT02447315 still recruiting?

NCT02447315 is currently completed. Last updated 10 August 2015.

Last reviewed 2015-08-10 · How we verify

NCT02447315

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1 Study to Investigate the Effect of Oral Doses of Pilocarpine on Salivary Secretion and Static Pupillometry in Healthy Subjects

Completed Phase 1 Last updated 10 August 2015

What this trial tests

Phase 1 trial testing Pilocarpine in Healthy Subjects in 12 participants. Completed in 1 June 2015.

Timeline

1 May 2015

Primary endpoint
1 June 2015

1 June 2015

Quick facts

Lead sponsor	Astellas Pharma Europe B.V.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	basic science
Enrollment	12
Start date	1 May 2015
Primary completion	1 June 2015
Estimated completion	1 June 2015
Sites	1 location across United Kingdom

Drugs / interventions tested

Pilocarpine (PILOCARPINE) — full drug profile →
Placebo

Conditions studied

Healthy Subjects — all drugs for Healthy Subjects →

Sponsor

Astellas Pharma Europe B.V. — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy Subjects. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Pharmacodynamic parameter salivary secretion at specified time points
Time frame: Days 1-5
Measure (mg/min) salivary secretion at specific timepoints
Pharmacodynamics assessed by area under the effect-time curve (AUE), saliva (AUEsal)
Time frame: Days 1-5
Pharmacodynamics assessed by maximal effect (Emax), saliva (Emax, sal)
Time frame: Days 1-5
Pharmacodynamics assessed by time at which the maximum salivary flow occurs (tmax, sal)
Time frame: Days 1-5

Sponsor's own description

The purpose of this study is to evaluate the pharmacodynamic effect of oral doses of pilocarpine on salivary secretion in healthy male and female subjects. In addition, pharmacodynamic effect on static pupillometry will be evaluated as well as pharmacokinetics and safety and tolerability of oral doses of pilocarpine in healthy subjects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Pilocarpine

Trials testing the same drug.

NCT06752278 — Efficacy of Pilocarpine As a Secretagogue Versus Artificial Tears for the Treatment of Dry Eye · NA · completed
NCT04675151 — Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia · Phase 2 · completed
NCT04005079 — Pilocarpine After Combined Cataract/Trabectome Surgery · Phase 3 · withdrawn
NCT03460964 — Measuring Sweat Glucose of Patients With Diabetes - The ENGAGE Study · NA · terminated
NCT02935894 — Investigating the Stability, Variability and Mechanism of Incorporation of Lipid Mediators Into Eccrine Sweat · NA · completed

Other recruiting trials for Healthy Subjects

Currently open trials in the same condition.

NCT07222020 — Phase 1 Study of Intravaginal KB15A · Phase 1 · recruiting
NCT07350538 — The Critical Link Between Gut Microbiome Dysfunction, Cravings and Relapse: RECLAIM-GUT TRIAL · NA · active not recruiting
NCT07304791 — This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and P · Phase 1 · recruiting
NCT07059858 — Bladder and Bowel Functions, Participation and Quality of Life in Children With Intellectual Disabilities · recruiting
NCT07331389 — A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin · Phase 1 · recruiting

Other Astellas Pharma Europe B.V. trials

Trials by the same sponsor.

NCT03702777 — A Study of ASP8302 in Participants With Underactive Bladder · Phase 2 · completed
NCT04742517 — A Study of MA-0217 (ASP1128) in Healthy Adult Subjects and Healthy Elderly Subjects · Phase 1 · completed
NCT03282318 — A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Sub · Phase 2 · completed
NCT03108755 — A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP7713 in Healthy Non-Japanese Adult and Elderly Sub · Phase 1 · completed
NCT02788123 — A Study To Assess The Efficacy And Safety Of Bismuth Tripotassium Dicitrate (De-Nol) In Combination With Pantoprazole An · Phase 4 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02447315 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Astellas Pharma Europe B.V.
Last refreshed: 10 August 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02447315.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing